---
title: "Ascendis Pharma director Jean-Jacques Bienaime buys USD 492,079 of common shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296284390.md"
description: "Ascendis Pharma director Jean-Jacques Bienaime purchased 2,000 ordinary shares in open-market transactions. The weighted-average purchase prices were USD 245.85 and USD 246.91 per share, totaling approximately USD 492,079. Following these purchases, Bienaime's direct holding increased to 2,900 ordinary shares."
datetime: "2026-08-19T01:03:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296284390.md)
  - [en](https://longbridge.com/en/news/296284390.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296284390.md)
generator: "portal-rs"
---

# Ascendis Pharma director Jean-Jacques Bienaime buys USD 492,079 of common shares

-   Ascendis Pharma director Jean Jacques Bienaime bought 2,000 ordinary shares in open-market purchases. \* Purchases were executed at weighted-average prices of USD 245.85 and USD 246.91. \* Bienaime’s direct holding rose to 2,900 ordinary shares following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascendis Pharma A/S published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001610717-26-000360), on August 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ASND.US](https://longbridge.com/en/quote/ASND.US.md)

## Related News & Research

- [Ascendis Pharma Director’s Bold Stock Move Grabs Investor Attention](https://longbridge.com/en/news/297979377.md)
- [Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes](https://longbridge.com/en/news/297515082.md)
- [How BioMarin’s Navepegritide Settlement and Royalty Deal with Ascendis Could Shape BioMarin (BMRN) Investors](https://longbridge.com/en/news/297761649.md)
- [Sansuy board member boosts stake by R$ 5,766 in August on open-market buys](https://longbridge.com/en/news/298033195.md)
- [Cambuci board member lifts stake by R$ 41,589.87 via open-market buys](https://longbridge.com/en/news/297930625.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**